Iconictherapeutics.com has Server used IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2003-03-25 (17 years, 184 days) and hosted in Scottsdale United States, server ping response time 94 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Iconictherapeutics keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Iconic therapeutics
2 Iconic therapeutics south san francisco

Hosting Provider

Website: Iconictherapeutics.com
Hostname: redirect-v225.secureserver.net
Region: AZ
City: Scottsdale
Postal Code: 85260
Latitude: 33.61190032959
Longitude: -111.89060211182
Area Code: 480
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain

New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Precisevac.com (8 seconds ago)

   » Thcmmarketplace.com (4 seconds ago)

   » Randsequipment.com (22 seconds ago)

   » Iconictherapeutics.com (0 seconds ago)

   » Mthandyland.net (6 seconds ago)

   » Total-transportation.com (15 seconds ago)

   » Gogohopping.com (11 seconds ago)

   » Shfarmsupply.com (4 seconds ago)

   » 345new.com (4 seconds ago)

   » Optimumscr.com (17 seconds ago)

Results For Websites Listing

Found 72 Websites with content related to this domain, It is result after search with search engine


(10 day ago) Tissue Factor Science Iconic Therapeutics is leveraging its deep insight into the role of tissue factor in inflammation and angiogenesis to develop breakthrough medicines for ophthalmology and oncology indications. Learn More Ophthalmology With our investigational tissue


DA: 22 PA: 22 MOZ Rank: 23

Iconic Therapeutics Inc - Company Profile and News

(2 month ago) Iconic Therapeutics, Inc. was founded in 2006. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary


DA: 17 PA: 28 MOZ Rank: 45

Iconic Therapeutics | VentureRadar

(16 day ago) Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company's lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD.

https://www.ventureradar.com/organisation/Iconic Therapeutics/ce12712b-fe25-4c76-91fc-9d0eac72fa24

DA: 20 PA: 50 MOZ Rank: 92

Exelixis and Iconic Therapeutics Enter into Exclusive

(1 year ago) Iconic Therapeutics, Inc. is a venture-backed biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and


DA: 20 PA: 29 MOZ Rank: 49


(11 day ago) Ms. Lane as 20+ years of experience in project management, and study site monitoring in Phase I-IV clinical trials. She has served as VP of clinical operations in Adverum Biotechnologies and leader of multi-disciplinary project teams in Sanofi, Pfizer, Genentech, Roche, Geron, Avalanche Biotech and Iconic Therapeutics. .


DA: 21 PA: 21 MOZ Rank: 22

iCo Therapeutics – Your Health Is Your Most Precious Asset

(9 day ago) See the latest investor updates, news releases, and review recent presentations and the upcoming Events where iCo will be featured and discussed.


DA: 19 PA: 19 MOZ Rank: 20

Stuart Therapeutics

(10 day ago) Stuart Therapeutics’ first drug candidate is ST-100, a novel therapeutic in drop formulation for Dry Eye Disease (DED). Unlike most therapeutic solutions for DED, ST-100 is a fast acting, broadly applicable option for patients that has shown an ability to provide complete corneal healing in less than 24 hours in animal studies.


DA: 26 PA: 26 MOZ Rank: 27

ONL Therapeutics – Visionary Science

(10 day ago) OUR SCIENCE. ONL1204, the company’s lead therapeutic candidate is a first-in-class small peptide Fas inhibitor designed to protect the retina from cell death via both direct and inflammatory signaling in a range of retinal diseases.


DA: 23 PA: 23 MOZ Rank: 24

Home - Invex Therapeutics Ltd

(10 day ago) Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.


DA: 21 PA: 21 MOZ Rank: 22

Recently Analyzed Sites